Dia-Präsentation von Merck Gesellschaft mbH. Micardis(R) - Micardis Plus(R) - Effekte bei Zielorganschädigung (16 Abbildungen) Übersicht | ||||||||||||||||||
Abbildung 6: Telmisartan - Renoprotektiver Effekt Ucak et al. conducted an open-label study comparing lisinopril 20 mg as monotherapy and in combination with telmisartan 80 mg in 100 type 2 diabetics with microalbuminuria (30–300 mg/24 h) who had been receiving ACE inhibitors for at least 6 months previously.1 At baseline, albuminuria was 264 mg/24 h in the lisinopril group and 256 mg/24 h in the combination therapy group. After 12 months, albuminuria had decreased to 186 mg/24 h with lisinopril and 144 mg/24 h with combination therapy (P<0.001). Both treatment arms had a similar decrease in blood pressure (SBP/DBP decreased by 1/2 and 1/4 mmHg in the lisinopril monotherapy and lisinopril/telmisartan combination therapy, respectively). 1. Ucak S, et al. Combination of telmisartan and ACE-I significantly reduces urinary albumin excretion in hypertensive patients with type 2 diabetes. Program and abstracts of the 38th Annual Meeting of the European Association for the Study of Diabetes Budapest, Hungary: September 1–5, 2002. |
Abbildung 6: Telmisartan - Renoprotektiver Effekt
Ucak et al. conducted an open-label study comparing lisinopril 20 mg as monotherapy and in combination with telmisartan 80 mg in 100 type 2 diabetics with microalbuminuria (30–300 mg/24 h) who had been receiving ACE inhibitors for at least 6 months previously.1 At baseline, albuminuria was 264 mg/24 h in the lisinopril group and 256 mg/24 h in the combination therapy group. After 12 months, albuminuria had decreased to 186 mg/24 h with lisinopril and 144 mg/24 h with combination therapy (P<0.001). Both treatment arms had a similar decrease in blood pressure (SBP/DBP decreased by 1/2 and 1/4 mmHg in the lisinopril monotherapy and lisinopril/telmisartan combination therapy, respectively). 1. Ucak S, et al. Combination of telmisartan and ACE-I significantly reduces urinary albumin excretion in hypertensive patients with type 2 diabetes. Program and abstracts of the 38th Annual Meeting of the European Association for the Study of Diabetes Budapest, Hungary: September 1–5, 2002. |
